TheStreet
Your browser is not supported. Please upgrade to one of the following browsers:

Google Chrome

Mozilla Firefox

Apple Safari

Microsoft Internet Explorer 9+

You may proceed to the site by clicking here, however some pages might not work correctly.
ip-192-168-66-134
JOIN JIM CRAMER'S INVESTING CLUB
  • Log In
    Your Account
    Account Preferences Newsletters Alerts
    Logout
  • Newsletters
  • Subscribe
    Access insights and guidance from our Wall Street pros. Find the product that's right for you.
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement Daily
    • Stocks Under $10
    • Top Stocks
    • Trifecta Stocks
    • Real Money Pro Portfolio
    • Chairman's Club
    • Compare All
  • Jim Cramer
    • Action Alerts PLUS
    • Cramer's Blog
    • Cramer's Monthly Call
    • Jim Cramer's Best Stocks
    • Cramer's Articles
    • Mad Money
    • 25 Rules for Investing
    • 10 Commandments
  • Investing
    • Earnings
    • Funds
    • Bitcoin
    • Fixed Income
    • Options
    • Futures
    • Stocks
    • ETFs
  • Personal Finance
    • Credit Cards
    • Debt Management
    • Mortgages
    • Real Estate
    • Taxes
    • Education
    • Savings
    • Insurance
  • Retirement
    • Social Security
    • Estate Planning
    • IRAs
    • 401k
  • Technology
    • Cybersecurity
  • Markets
    • Currencies
    • Rates and Bonds
    • Commodities
    • Emerging Markets
    • Mergers and Acquisitions
    • IPOs
    • Bankruptcy
    • Regulation
    • Corporate Governance
  • How-To
  • Video
TheStreet Ratings

Research Center
Reports
Stock Upgrades & Downgrades

Gritstone Oncology, Inc.

Find Ratings Reports
GRTS : NASDAQ :
$8.60 -0.18 | -2.10%
Today's Range: 8.31 - 8.85
Avg. Daily Volume: 0
04/20/21 - 3:59 PM ET
Rating Summary Rating Detail Financial Analysis Peer Group

Financial Analysis


GRITSTONE ONCOLOGY's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its subsector. GRITSTONE ONCOLOGY is extremely liquid. Currently, the Quick Ratio is 6.34 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 24.11% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY20 Q4 FY19
Net Sales ($mil)1.350.88
EBITDA ($mil)-25.45-26.87
EBIT ($mil)-27.15-28.31
Net Income ($mil)-27.17-27.7


Balance Sheet Q4 FY20 Q4 FY19
Cash & Equiv. ($mil)171.06127.78
Total Assets ($mil)221.57184.39
Total Debt ($mil)25.123.49
Equity ($mil)166.74134.34


Profitability Q4 FY20 Q4 FY19
Gross Profit Margin-1886.88-3039.71
EBITDA Margin-1886.87-3039.7
Operating Margin-2012.38-3202.83
Sales Turnover0.020.02
Return on Assets-47.53-51.21
Return on Equity-63.16-70.29
Debt Q4 FY20 Q4 FY19
Current Ratio6.56.73
Debt/Capital0.130.15
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY20 Q4 FY19
Shares outstanding (mil)47.5536.33
Div / share0.00.0
EPS-0.69-0.77
Book value / share3.513.7
Institutional Own % n/a n/a
Avg Daily Volume3371848.0432791.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.52 indicates a significant discount versus the S&P 500 average of 4.38 and a significant discount versus the subsector average of 10.89. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, GRITSTONE ONCOLOGY proves to trade at a discount to investment alternatives.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
GRTS NM Peers 150.51   GRTS NM Peers 27.32

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

GRTS's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

GRTS's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
GRTS NM Peers 20.46   GRTS NA Peers 0.68

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

GRTS's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
GRTS 2.52 Peers 10.89   GRTS 0.36 Peers 21.29

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

GRTS is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, GRTS is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
GRTS 104.17 Peers 1178.26   GRTS -7.52 Peers 978.73

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

GRTS is trading at a significant discount to its subsector on this measurement.

 

Lower. A sales growth rate that trails the subsector implies that a company is losing market share.

GRTS significantly trails its peers on the basis of sales growth.

 

 

Latest Stock Upgrades/Downgrades

View more upgrades/downgrades >>
Ratings Guide
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • Video
  • Opinion
  • Politics
  • Lifestyle

Featured Topics

  • Mad Money
  • Stock Market Today
  • Dow Jones Today
  • Stocks
  • Funds
  • ETFs
  • Bitcoin
  • Travel
  • Sports
  • Health
  • Food and Drink
  • Cybersecurity
  • Penny Stocks
  • How to Invest in Stocks
  • Social Security
  • 401K
  • IRAs
  • Taxes
  • Index Funds
  • Roth IRAs
  • Home Insurance
  • Health Insurance
  • Disability Insurance
  • Prime Day

Popular Pages

  • Best Stocks
  • Best Stocks to Buy
  • Earnings Calendar
  • Ex Dividend Date
  • Mutual Fund Ratings
  • Best Online Brokers
  • Rates and Bonds
  • Commodities
  • Treasury Bonds
  • Junk Bonds
  • Corporate Bonds
  • Municipal Bonds

Subscriptions

  • Action Alerts PLUS
  • Quant Ratings
  • Real Money
  • Real Money Pro
  • Retirement Daily
  • Stocks Under $10
  • Top Stocks
  • Trifecta Stocks
  • RMP Portfolio
  • Chairman's Club

Stay Connected

  • Sitemap
  • Feedback
  • About Us
  • Investor Relations
  • Advertise
  • Reprints
  • Customer Service
  • Employment
  • Privacy Policy
  • Terms of Use
  • Topic Archive
  • Video Sitemap
  • Data
  • Affiliate
  • Press Room
© 1996- TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.

  • INVEST WITH CRAMER FREE for 14 Days→
    • Jim Cramer
      • Action Alerts PLUS
      • Cramer's Blog
      • Cramer's Monthly Call
      • Jim Cramer's Best Stocks
      • Cramer's Articles
      • Mad Money
      • 25 Rules for Investing
      • 10 Commandments
    • Investing
      • Earnings
      • Funds
      • Bitcoin
      • Fixed Income
      • Options
      • Futures
      • Stocks
      • ETFs
    • Personal Finance
      • Credit Cards
      • Debt Management
      • Mortgages
      • Real Estate
      • Taxes
      • Education
      • Savings
      • Insurance
    • Retirement
      • Social Security
      • Estate Planning
      • IRAs
      • 401k
    • Technology
      • Cybersecurity
    • Markets
      • Currencies
      • Rates and Bonds
      • Commodities
      • Emerging Markets
      • Mergers and Acquisitions
      • IPOs
      • Bankruptcy
      • Regulation
      • Corporate Governance
    • How-To
    • Video
    Privacy Policy|Terms of Use
    © 1996-2018 TheStreet Inc. All rights reserved